The Versius surgical system from Cambridge Medical Robotics is the first UK based robotic platform to become commercially available. This is a prospective series in accordance with the IDEAL development framework for surgical innovation reporting the clinical implementation and initial experience using this robotic platform. Patients with colorectal cancer were included. Exclusion criteria included T4 tumours, ultra-low rectal cancer and severe co-morbidity (ASA ≥ 3). Institutional ethical approval was obtained, and patients were counselled pre-operatively with informed consent. Patients underwent colorectal resection using the Verisus Surgical System. Procedures were anticipated as hybrid operations (laparoscopic/robotic) consistent with a proof of concept/technical feasibility study. Main outcome measures included operative time, complication rates, and pathological results. Thirty-two patients (15 males) underwent colorectal cancer resections. Mean age was 68 years (27yrs-85yrs). Estimated blood loss was 150mls; range (